Description: XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.
Home Page: www.xtlbio.com
XTLB Technical Analysis
5 Badner Street
Ramat Gan,
5218102
Israel
Phone:
972 3 611 6600
Officers
| Name | Title |
|---|---|
| Mr. Shlomo Spokone Shalev | CEO & Director |
| Mr. Itay Weinstein | Chief Financial Officer |
| Mr. Ronen Kantor | Company Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 4.6286 |
| Price-to-Book MRQ: | 1.4587 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2005-09-01 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |